Renal cell carcinomas (RCCs) often behave aggressively and are associated with a poor
prognosis. Tumors are both chemoresistant and radioresistant and surgery is the only known …

PURPOSE:: Renal cell carcinoma (RCC) has traditionally been staged using a purely anatomical
staging system. Although current staging systems provide good prognostic information, …

Purpose : We provide a current review of the management of advanced renal cell carcinoma.
Materials and Methods : A comprehensive literature review of peer reviewed articles which …

Background Since sunitinib malate has shown activity in two uncontrolled studies in patients
with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a …

Background Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited
efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of …

Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian
target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a …

Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa
(IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic …

Purpose Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor
suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: …

BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …

Purpose To analyze to what extent histologic subtype is of prognostic importance in renal
cell carcinoma based on a large, international, multicenter experience. Patients and Methods …